drugset / Trial / NCT00616642
Rosiglitazone in Treating Patients With Pituitary Tumors
Phase 2
Terminated
1 enrolled
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Rosiglitazone may help pituitary adenoma cells become more like normal cells, and grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed or residual or recurrent pituitary adenoma.
Timeline
- Start
- 2006-10
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosiglitazone | Small molecule | 8 mg | Oral |